Independent of KRAS mutation status, substantial and statistically significant antineoplastic effects of CDK2 inhibition were observed in murine syngeneic and human PDX lung cancer models after CYC065 treatment, repressing primary and metastatic lung cancer growth in vivo (19, 20). Here, KRAS is linked to lung carcinoma.